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Background: Chronic neuroinflammation and calcium (Ca+2) dysregulation are both components of Alzheimer’s disease.
Prolonged neuroinflammation produces elevation of pro-inflammatory cytokines and reactive oxygen species which can
alter neuronal Ca+2 homeostasis via L-type voltage-dependent Ca+2 channels (L-VDCCs) and ryanodine receptors (RyRs).
Chronic neuroinflammation also leads to deficits in spatial memory, which may be related to Ca+2 dysregulation.
Methods: The studies herein use an in vivo model of chronic neuroinflammation: rats were infused intraventricularly with
a continuous small dose of lipopolysaccharide (LPS) or artificial cerebrospinal fluid (aCSF) for 28 days. The rats were
treated with the L-VDCC antagonist nimodipine or the RyR antagonist dantrolene.
Results: LPS-infused rats had significant memory deficits in the Morris water maze, and this deficit was ameliorated by
treatment with nimodipine. Synaptosomes from LPS-infused rats had increased Ca+2 uptake, which was reduced by a
blockade of L-VDCCs either in vivo or ex vivo.
Conclusions: Taken together, these data indicate that Ca+2 dysregulation during chronic neuroinflammation is
partially dependent on increases in L-VDCC function. However, blockade of the RyRs also slightly improved
spatial memory of the LPS-infused rats, demonstrating that other Ca+2 channels are dysregulated during chronic
neuroinflammation. Ca+2-dependent immediate early gene expression was reduced in LPS-infused rats treated with
dantrolene or nimodipine, indicating normalized synaptic function that may underlie improvements in spatial memory.
Pro-inflammatory markers are also reduced in LPS-infused rats treated with either drug. Overall, these data suggest that
Ca+2 dysregulation via L-VDCCs and RyRs play a crucial role in memory deficits resulting from chronic neuroinflammation.
Keywords: Calcium, Neuroinflammation, Ryanodine receptors, L-type voltage-dependent calcium channels,
Spatial memoryIntroduction
Chronic neuroinflammation is a component of normal
aging and may contribute to age-related cognitive decline
as well as neurodegenerative disorders such as Alzheimer’s
disease (AD; [1]). One of the primary effector cells of neu-
roinflammation are microglia, the resident macrophages of
the central nervous system. Normally, microglia contribute* Correspondence: wenk.6@osu.edu
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unless otherwise stated.to normal neuronal function, but chronic microglia activa-
tion can cause damage to nearby neurons [2]. Several
aspects of AD can be replicated by chronic infusion of
lipopolysaccharide (LPS) into the fourth ventricle of
young rats ([3,4]. Chronic neuroinflammation in young
rats impairs performance in a variety of memory tasks
[5] and such memory impairments are associated with
long-term potentiation (LTP) deficits [6].
Ca+2 handling is altered in non-neuronal tissues derived
from AD patients and family members [7]. Epidemiological
studies have shown that the use of L-type voltage-dependenthis is an Open Access article distributed under the terms of the Creative
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diovascular conditions is associated with a reduced incidence
of AD in [8] and patients treated with the L-VDCC antagon-
ist nimodipine have improved cognitive scores compared to
placebo-treated patients [9]. Ryanodine receptors (RyRs)
may represent a novel target for treatment of Alzheimer’s
disease. RyR expression is altered in patients with AD and
mild cognitive impairment [10], and patients with sporadic
AD both have L-VDCC and RyR mutations that interact to
increase and have amyloid deposition [11], demonstrating
the importance of these two channels in the AD pathology.
In addition to normalizing calcium dysregulation, targeting
of RyRs and L-VDCCs in vitro is anti-inflammatory [12-14],
and previous epidemiological studies have revealed that use
of other anti-inflammatory drugs such as nonsteroid
anti-inflammatory drugs (NSAIDs) also reduces Alzheimer’s
disease incidence [15].
Neuroinflammation and neuronal Ca+2 dysregulation
may interact, synergistically leading to memory deficits.
Neuroinflammation increases glutamatergic activity by
suppression of glutamate transport ([13,16-18]) while
potentiating activity of N-methyl D-aspartate receptors
(NMDARs; [19-21]). Similarly, pro-inflammatory cyto-
kines and nitric oxide (NO) can increase the function
of L-VDCCs [22] and RyRs [23,24]. Both NMDAR-
dependent and L-VDCC-dependent LTP are disrupted
during chronic neuroinflammation [25]. Additionally,
the function of RyRs and L-VDCCs are linked not only
to each other but also to the function of NMDARs
[26-28]. RyRs interact with NMDARs by amplifying
NMDAR Ca+2 signals [26], while L-VDCCs can decre-
ment relevant NMDAR event-related signaling by length-
ening the after hyperpolarization [28]. Overall, these data
suggest that these channels can all act synergistically to
increase intracellular Ca+2 concentration during neuroin-
flammation and disrupt normal processes that underlie
memory. Increased intracellular Ca+2 could lead to mem-
ory deficits via dysregulated activation of Ca+2-dependent
kinases and subsequent production of immediate early
genes (IEGs) such as activity-regulated cytoskeleton-
associated protein (Arc).
Overall, these data have led to the following hypotheses. 1)
If neuroinflammation leads to increases in intracellular Ca+2
levels, then increased Arc production should be observed in
tissue from rats chronically infused with LPS, since
Arc induction is Ca+2 dependent [29]. Furthermore,
transport of Ca+2 should be observed directly in synap-
tosomes generated from the hippocampus of these
rats. 2) If neuroinflammation-induced memory deficits
are due to increased intracellular Ca+2 and dysregula-
tion of L-VDCCs and/or RyRs, then pharmacological
blockade of these channels should improve spatial
memory deficits and normalize Ca+2 levels and activity
of Ca+2-dependent markers.Methods
Subjects and surgical procedures
The subjects were male F-344 (Harlan, Indianapolis, IN,
USA) rats, 3 months old, individually housed with ad
libitum access to food and water and maintained on a
reverse 12/12 light/dark cycle with lights off at 8 AM.
Artificial cerebrospinal fluid (aCSF, 140 mM NaCl, 3.0 mM
KCl, 2.5 mM CaCl2, 1.0 mM MgCl2, 1.2 mM Na2HPO4,
pH 7.4; n = 40) or LPS (Sigma, St. Louis, MO, USA,
Escherichia coli serotype 055:B5 TCA extraction, 1.0 mg/ml
dissolved in aCSF, n = 43) was loaded into an osmotic mini-
pump (Alzet model #2004, with a rate of 0.25 μl/hr, Durect
Corp., Cupertino, CA, USA) and infused into the brain for
28 days via a cannula surgically implanted into the fourth
ventricle as previously described [30]. The day after the
osmotic minipump was implanted, rats began to receive
daily subcutaneous drug injections at a volume of 1 ml/kg
per day with a vehicle (polyethylene glycol 300, Thermo
Fisher Scientific, Waltham, MA, USA), dantrolene sodium
salt (5 mg/kg/day, Sigma), or nimodipine (5 mg/kg/day,
Sigma), resulting in six group + drug treatment groups
(aCSF + vehicle, n = 14; aCSF + dantrolene, n = 13; aCSF +
nimodipine, n = 13; LPS + vehicle, n = 16; LPS + dantrolene,
n = 14; LPS + nimodipine, n = 14). Body weights were mon-
itored daily, and rats were given saline injections and sup-
plemental food postoperatively to prevent dehydration and
weight loss. This research was carried out in accordance
with the National Institutes of Health Guide for the
Care and Use of Laboratory Animals (NIH Publication
No. 80–23) and The Ohio State University Institutional
Animal Care and Use Committee.
Behavioral testing
The rats were handled daily for 1 week prior to surgery
and daily up until behavioral testing, which took place
on the third week following surgery. Spatial learning
was assessed in the Morris water maze (MWM), using
a 170-cm diameter pool with gray walls surrounded by
multiple visual distal and proximal cues. The water was
maintained at room temperature (RT; 21°C to 22°C).
During the hidden platform portion of the task, a circular
escape platform was present in a consistent location and
submerged 2.5 cm below the water surface. The rats were
tracked using overhead cameras and Noldus Ethovision
3.1 tracking and analysis stem (Noldus, Lessburg, VA,
USA). On the first day, rats were placed on the hidden
platform for 30 s prior to the trial. Each rat performed six
trials per day separated by a 60-min inter-trial interval for
four consecutive days. The rat was released into the water
at one of six randomized locations which were varied such
that rats were could not take the same path to the hidden
platform more than once per day. After the rat located the
hidden platform or swam for a maximum of 60 s, it was
placed on the platform for 30 s. After the last training trial
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where the platform was removed from the pool. Finally, at
the end of the fourth day, the rats were tested in a visual
platform test where the platform was moved to a new
quadrant and raised 2 cm above the surface of the water
in order to control for any group- or drug-related differ-
ences in visual acuity or swimming ability. All rats across
all groups were able to locate the visible platform. Three
days after the conclusion of the water maze task, in order
to assess expression of the behaviorally induced immedi-
ate early gene Arc, rats were exposed to a novel context
30 min prior to sacrifice. The novel context was an explor-
ation box (36 × 48 cm) surrounded by proximal and distal
visual stimuli.
Tissue collection
All of the rats were deeply anesthetized using isoflurane
prior to sacrifice. One cohort of rats was used for hist-
ology (n = 6 per each group + drug) and another used
for biochemistry (n = 7 to 10 per each group + drug).
The histology cohort underwent transcardiac perfusion
with cold saline containing 1 U/ml heparin followed by
4% paraformaldehyde in 0.1 M phosphate buffer, pH 7.4.
The brains were post-fixed overnight in fixative and then
stored at 4°C in phosphate-buffered saline (PBS), pH 7.4.
The biochemistry cohort was rapidly decapitated and their
hippocampi dissected on ice and separated such that the
right or left sides were randomly chosen for either protein
or gene expression analysis. The hippocampi were stored
at −80°C until RNA or protein extraction. A separate
cohort of rats was used for 3H-radioligand binding assays,
cell isolation procedures, and generation of synaptosomes
for use in the 45Ca+2 uptake (n = 10/group). For these rats,
one hippocampus was used immediately for the gener-
ation of synaptosomes.
Immunohistochemistry
Free-floating coronal sections (40-μm thickness) were
generated using a vibratome and stained using standard
avidin/biotin-peroxidase-labeling methods as previously
described [31]. The rabbit polyclonal antibody against
Arc (final dilution 1:2,000; Synaptic Systems, Goettingen,
Germany) was used to label behaviorally activated neu-
rons; the mouse monoclonal antibody against OX-6
(final dilution 1:200; BD Pharmigen, San Diego, CA,
USA) was used to label major histocompatibility com-
plex II (MHC-II) on activated microglia; and the mouse
monoclonal antibody against glial fibrillary acid protein
(GFAP; final dilution 1:2,000; Millipore Chemicon, Billerica,
MA, USA) was used to quantify astrocyte activation.
Briefly, endogenous peroxidase activity was quenched
and nonspecific binding was blocked with 5% normal goat
serum (NGS) in PBS (OX-6 and GFAP) or Tris-buffered
saline (TBS) with 5% Tween (Arc). Sections were thenincubated overnight at 4°C in primary antibody diluted in
the same blocking solution. The next day, sections were
rinsed and then incubated for 1.5 h at RT in biotinylated
secondary antibody from the appropriate species (final
dilution 1:200, Vector, Burlingame, CA, USA). Sections
were then rinsed and incubated for 1 h at RT with
avidin-biotinylated horseradish peroxidase (Vectastain,
ABC kit, Vector). After another rinse, sections were incu-
bated with 0.05% 3, 3′-diaminobenzidine tetrahydrochloride
(Vector) as a chromogen. The reaction was stopped by rins-
ing the sections with PBS. No staining was detected in the
absence of primary or secondary antibodies. Sections were
mounted on superfrost slides, air-dried, dehydrated with a
series of ethanol and xylene rinses, and cover slipped with
cytoseal (Allan Scientific, Kalamazoo, MI, USA) mounting
medium. Images of the hippocampi were captured with light
microscopy, stitched together, and analyzed with a Nikon
90i system with a DS-5 M-L1 digital camera using Elements
3.1 Software (Nikon Instruments, Melville, NY, USA).
Subfields of interested were determined as previously
reported [32]. OX-6 was quantified using automated
cell-counting methods as previously described [6]. OX-6
immunoreactive objects larger than 65 mm2 were included
in analysis, and data are expressed as number of objects
per mm2. Arc and GFAP were quantified using intensity
densitometry and data are expressed as % area (of the
region of interest).
RNA isolation and quantitative polymerase chain reaction
Total RNA was isolated from hippocampi with phenol-
chloroform extraction using PureZol (Bio-Rad, Hercules,
CA) followed by cleanup using NucleoSpin RNA II kits
(Machery-Nagel, Düren, Germany) according to the manu-
facturers’ instructions. RNA quantity was measured using
a Synergy Plate reader equipped with a Take-3 plate
(Bio-Tek, Winooski, VT, USA) and 1 μg from each sample
was used to generate cDNA with iScript reverse transcrip-
tion Supermix kit (Bio-Rad) using a C1000 Thermal Cycler
(Bio-Rad). Selected RNA samples were run without reverse
polymerase as a control to ensure no contamination from
genomic DNA. Primers were designed using the Primer-
Quest software (Integrated DNA Technologies, Coralville,
IA, USA; Table 1). Gene expression was quantified
using SsoAdvanced Universal SYBR Green (Bio-Rad)
quantitative polymerase chain reaction (qPCR) on a CFX96
Real-Time PCR detection system (Bio-Rad). Glyceraldehyde-
3-phosphate dehydrogenase (GAPDH) was used as a
reference gene. Data were analyzed using the comparative
threshold cycle method with results expressed as a fold
change versus aCSF + vehicle rats.
45Ca+2 synaptosomal uptake
A 45Ca+2 synaptosomal uptake assay was used in order
to determine whether LPS treatment would increase
Table 1 Primer sequences
Target Accession # Forward Reverse
GAPDH NM_017008 TGACTCTACCCACGGCAAGTTCAA ACGACATACTCAGCACCAGCATCA
RyR1 AF112256 TGCGCTCCAACCAGGATCTCATTA TCACCTCGAAGTACCACTTGCCATAC
RyR2 AF112257 GGACTTGAAGGAACTGACGGAGGAAA CACTGAGACCAGCATTTGGGTTGTG
RyR3 AF130881 TGGCCTCCTGGCTGTAGTTGTTTA ACCTGCTCTTACGCCCACATACAT
VDCC a1c NM_012517 GGCTATGAGTTGCCCTGGGTGTATTT CGAGCTTTGGCTTTCTCCCTCTCTTT
VDCC a1d NM_017298 TGCATGACATTGGGCCAGAAATCC AGTTTCCAAGCAGGGCACCATTTC
IL-1β NM_031512 ACCTGCTAGTGTGTGATGTTCCCA AGGTGGAGAGCTTTCAGCTCACAT
TNFα X66539.1 CTGGCCAATGGCATGGATCTCAAA AGCCTTGTCCCTTGAAGAGAACCT
TGFβ NM_021578 TGATACGCCTGAGTGGCTGTCTTT TTTGCTGTCACAAGAGCAGTGAGC
iNOS NM_012611 AGTTTCCAAGCAGGGCACCATTTC TGGGTGTCAGAGTCTTGTGCCTTT
ARC NM_017134 AGCTACCTGCTGGGAAGGAAGAAA CTTCTCTGTAAGATAGGCCTCCCACAAC
CD200 ligand NM_031518 CCTGAACGTGTTTCCCTGGTCTACTT GTCAAATCCCTCACAGGCTTCCTTCT
CD200 receptor NM_023953 GCGGCTGAGTCAAGTTGTCCTGATA TGAAATAGAAGGGCAGCAGAGCAGAG
GAPDH glyceraldehyde-3-phosphate dehydrogenase, RyR ryanodine receptor, VDCC voltage-dependent Ca+2 channel, TNFα tumor necrosis factor alpha, TGFβ
transforming growth factor β, iNOS inducible nitric oxide synthase, ARC activity-regulated cytoskeleton-associated protein.
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be blocked by L-VDCC antagonism. Rats infused with
LPS or aCSF and treated with vehicle or nimodipine were
used for this assay. Synaptosomes were generated immedi-
ately from freshly dissected hippocampus by Teflon/glass
homogenization in 0.32 mM sucrose. Homogenates were
centrifuged at 3,000 RPM for 10 min at 4°C, followed by a
second centrifugation of the supernatant at 12,000 RPM
for 10 min at 4°C. The resulting pellet containing synapto-
somes was then resuspended in HEPES buffer (125 mM
NaCl, 3.5 mM KCl, 0.4 mM KH2PO4, 1.2 mM MgSO4
7(H2O), 10 mM d-glucose, 1 mM CaCl2, and 20 mM
HEPES) and placed on ice until use. An aliquot of each
sample was saved for protein quantification using a
Bio-Rad protein assay. HEPES buffer with 0.03 mM
nimodipine (Nim-HEPES) was prepared for use during
the blocked condition. HEPES buffer (60 μl) containing
0.01 μCi/μl of 45Ca+2 (Perkin Elmer, Boston, MA, USA)
was added to an incubation vial followed by 60 μl of either
HEPES buffer or Nim-HEPES. Synaptosomes (60 μl) were
added last and incubated at RT for 1 min and uptake was
stopped by filtration onto 0.45-μm nitrocellulose filters
(Millipore, Billerica, MA, USA). Filters were transferred
to scintillation vials and filled with scintillation fluid
(Formula 989, Perkin Elmer, Boston, MA, USA). Vials
were loaded into a liquid scintillation counter (1900
TR Tri Carb, Packard Instrument Company/Perkin-Elmer)
and number of decays per minute (DPMs) were counted
over 10 min per sample. All samples were run in triplicate,
plus blanks and external standards containing 10 μl of the
HEPES buffer containing 0.01 μCi/μl of 45Ca+2. For data
analysis, blank values were subtracted from the sample
values; DPMs were converted to moles of 45Ca+2 based
on the specific activity of the radioisotope and Curie’sconstant. Finally, the moles of 45Ca+2 were divided by
protein content of 60 μl of synaptosomes such that
data are presented as moles of 45Ca+2 per mg protein.
Statistical analyses
Statistical analyses were conducted using SigmaPlot 12.5
(Systat, San Jose, CA, USA). Analyses of variance (ANOVA)
were performed followed by either the Bonferroni correction
to counteract the problem of multiple post hoc comparisons
associated with analysis of the MWM data or Fisher’s
protected least significant difference for post hoc compari-
sons for the biochemistry and histology data. Graphs
display the mean plus standard error of the mean (SEM).
A P < 0.05 was considered statistically significant.
Results
Blockade of L-VDCCs or RyRs improves spatial memory
during chronic neuroinflammation
After 3 weeks of LPS or aCSF infusion and treatment with
vehicle, dantrolene, or nimodipine (n = 12 to 15/group),
we tested the rats’ performance in the MWM (Figure 1).
We examined the path length that rats took to locate the
hidden platform (Figure 1A), with longer path lengths in-
dicative of a spatial learning deficit. We first performed a
three-way ANOVA (infusion group × drug group × day of
testing) and then a post hoc two-way repeated measures
(RM)-ANOVA (combining infusion group and drug
group × day of testing) as described previously when
using a similarly designed study [33]. The three-way
ANOVA revealed significant memory deficits due to
LPS (F(1, 296) = 47.057, P < 0.001) and improvements
related to drug treatment (F(2, 296) = 5.050, P = 0.007)
and day (F(3, 296) = 45.838, P < 0.001). A post hoc two-way
RM-ANOVA revealed significant main effects due to the
Figure 1 Morris water maze spatial memory task performance
was assessed beginning in the third week of LPS (25 ng/hr) or
aCSF infusion and drug treatment with either vehicle,
dantrolene (5 mg/kg), or nimodipine (5 mg/kg) with 12 to 15
rats per infusion × drug group. Performance was assessed by (A)
path length and (C) latency to locate the hidden platform across
days of training, as well as average swim speed (B) across all trials.
Data expressed as mean ± SEM. *Indicates a significant difference
from treatment-matched aCSF controls, †indicates a significant
difference from LPS + vehicle rats within the LPS infusion group.
Significance determined by P < 0.05. LPS lipopolysaccharide, aCSF
artificial cerebrospinal fluid.
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provements related to day (F(3, 222) = 86.911, P < 0.001).
LPS + vehicle rats were significantly impaired compared toaCSF + vehicle rats on days 2 to 4 (P < 0.05). Nimodipine
treatment reversed LPS-induced deficits on days 3 and 4;
specifically, LPS + nimodipine-treated rats took signifi-
cantly (P < 0.05) shorter paths than LPS + vehicle rats and
took paths that were not significantly (P > 0.150) different
than their aCSF controls on days 3 and 4. Dantrolene
treatment did not improve LPS-induced deficits, as
LPS + dantrolene rats took significantly longer paths
than their controls on all the days of testing (P < 0.05)
and were not significantly different from the LPS + vehicle
rats (P > 0.05). We found that LPS-treated rats had signifi-
cantly faster swim speeds (Figure 1B; F(1, 74) = 29.173,
P < 0.001) and post hoc analysis showed that every LPS
group swam faster than their respective aCSF control
(P < 0.01). Despite their increased swimming speed, LPS-
infused rats also took more time to locate the hidden
platform (F(1, 296) = 33.340, P < 0.001), as measured by
latency to locate the hidden platform. Significant improve-
ments in latency were observed related to drug treatment
(F(2, 296) = 5.043, P = 0.007) and day of testing (F(3,296) =
80.392, P < 0.001). Similar to the results obtained with
distance taken to locate the hidden platform (Figure 1C).
A post hoc two-way RM-ANOVA revealed that the LPS +
vehicle rats took significantly (P < 0.05) more time than
the aCSF + vehicle rats to locate the hidden platform on
days 2 to 4. Nimodipine treatment completely reversed
LPS-induced deficits; specifically, the LPS + nimodipine-
treated rats took significantly (P < 0.05) less time than
the LPS + vehicle rats and were not significantly differ-
ent (P > 0.05) from their aCSF controls on days 2 to 4.
Dantrolene treatment led to a partial recovery of the LPS-
induced deficit; specifically, the LPS + dantrolene-treated
rats were not significantly different (P > 0.07) from their
aCSF controls on day 4. There was no difference between
any of the groups on day 1 (P > 0.05), suggesting that base-
line performance was not driving the performance differ-
ences observed on the subsequent days of testing. There
was also no difference between the aCSF groups on
any day (P > 0.05), indicating that neither dantrolene
nor nimodipine have cognitive enhancing effects or side
effects that are detrimental to learning. For the probe trial,
a two-way ANOVA revealed a significant main effect of
infusion group (F(1, 76) = 4.093, P = 0.047). Overall, poor
performance in the MWM was correlated with expression
of the CaV1.2 subunit of the L-VDCC (P < 0.05 by Pearson
correlation). Overall, these data indicate that LPS-induced
spatial memory deficits in the MWM can be reversed by
blockade of L-VDCCs, while blockade of RyRs only con-
fers a minor improvement.
Blockade of L-VDCCs or RyRs during chronic neuroinflammation
reduces aberrant expression of Arc
Due to the spatial memory improvements we observed
in LPS-infused rats treated with drugs that normalize or
Hopp et al. Journal of Neuroinflammation  (2015) 12:56 Page 6 of 14reduce intracellular Ca+2 concentration, we examined
levels of the IEG Arc, which is Ca+2 dependent. We ex-
amined expression of Arc protein in brains perfused
30 min after exposure to a novel spatial environment
and found region-specific changes in levels as measured
by immunohistochemistry and densitometry (Figure 2A,
B). A two-way ANOVA revealed that Arc expression in
the CA3 subfield of the hippocampus was increased by
LPS infusion (F(1, 129) = 14.614, P < 0.001) and trended
toward a main effect in the dentate gyrus (DG) subfield
(F(1, 129) = 3.712, P = 0.056), with a significant LPS and
drug interaction in the DG (F(2, 129) = 3.576, P = 0.031).
In the DG, treatment with dantrolene or nimodipine
reduced LPS-induced overexpression of Arc (P = 0.001
and P = 0.002, respectively) to aCSF levels. In the CA3,
dantrolene treatment led to a slight reduction in LPS-
induced Arc overexpression, and nimodipine treatment
significantly reduced Arc overexpression. In the CA1,
significant changes in Arc were related to drug treatment
(F(1, 129) = 5.043, P = 0.007). The CA1 of vehicle-treated
LPS-infused rats showed a trending increase in Arc
(P = 0.079) compared to aCSF controls, which was signifi-
cantly reduced by treatment with dantrolene or nimodipine
(P = 0.050 and P = 0.027, respectively). Overall, chronic
neuroinflammation increased expression of Arc andFigure 2 Hippocampal immunohistochemistry against Arc was quant
a novel context. (A) Representative slices of hippocampal Arc immunohis
(bottom row) and treatment with vehicle (first column), dantrolene (middle
immunostaining in CA1, CA1, and DG. Data expressed as mean± SEM. *Indicates
significant difference from LPS + vehicle rats within the LPS group. Significance d
fluid, DG dentate gyrus.reduction of intracellular Ca+2 via L-VDCC or RyR
blockade reduced these increases.
Ca+2 dysregulation during chronic neuroinflammation is
dependent on L-VDCC activity
We hypothesized that chronic LPS infusion was trigger-
ing Ca+2 dysregulation, since we found that LPS infusion
increases the Ca+2-dependent immediate early gene Arc
and that increase is blocked by Ca+2 channel blockers.
Ca+2 dysregulation in aging and AD has been associated
with increases in L-VDCCs or RyRs [10,34-36]. Here, we
examined hippocampal gene expression levels of the
L-VDCC subunits a1c (CaV1.2) and a1d (CaV1.3), both of
which are pharmacologically blocked by nimodipine, and
found no significant differences (P > 0.05) across any LPS
or drug treatments (Figure 3A, B). We also examined gene
expression of the three RyR isoforms and found no signifi-
cant differences (P > 0.05) across any LPS or drug treat-
ments (Figure 3C, D, E).
We tested whether chronic neuroinflammation would
functionally increase intracellular Ca+2 uptake by gener-
ating synaptosomes from fresh hippocampus from rats
infused with chronic LPS or aCSF and treated with ve-
hicle or nimodipine and measuring 45Ca+2 uptake using
liquid scintillation (Figure 4). At baseline (Figure 4A),ified across in brains perfused 30 min after rats were exposed to
tochemistry after 4 weeks of infusion with aCSF (top row) or LPS
column), or nimodipine (third column). (B) Quantification of Arc
a significant difference from treatment-matched aCSF controls, †indicates a
etermined by P< 0.05. LPS lipopolysaccharide, aCSF artificial cerebrospinal
Figure 3 Chronic LPS infusion did not change gene expression of either L-VDCC subunits or any of the RyR isoforms (A, B, C, D, E).
Data expressed as mean ± SEM. N.S. indicates no significant differences. Significance determined by P < 0.05. LPS lipopolysaccharide, aCSF artificial
cerebrospinal fluid, VDCC voltage-dependent Ca+2 channel, RyR ryanodine receptor.
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of drug (F(1, 34) = 4.410, P = 0.043) and a trend toward
a group main effect (F(1, 34) = 3.169, P = 0.084). Post hoc
analyses revealed that the LPS + vehicle rats had signifi-
cantly more moles of 45Ca+2 uptake per mg of protein
compared to the aCSF + vehicle rats (P = 0.034) as well as
compared to the LPS + nimodipine rats (P = 0.026). The
LPS + nimodipine rats were no different from the aCSF +
nimodipine rats or aCSF + vehicle rats (P > 0.5). These re-
sults demonstrated that increases in Ca+2 were dependent
on L-VDCC activity, since nimodipine was able to reverse
LPS-associated increases in Ca+2 uptake. In order to eluci-
date the role of L-VDCCs, we applied 10 μM of nimodi-
pine ex vivo to the same hippocampal synaptosomal
preparations (Figure 4B). With ex vivo nimodipine, there
were no differences across any LPS or drug treatments
(P > 0.2). When we examined the data with a three-way
ANOVA across the two conditions (baseline and blocked,
Figure 4C), we found a significant main effect of group
(F(1, 67) = 4.73, P = 0.033) and drug (F(1, 67) = 5.794,
P = 0.019), but not between conditions (F(1, 67) = 0.655,P = 0.421). Overall, these data demonstrate that there
is Ca+2 dysregulation during neuroinflammation that is
dependent on activity of L-VDCCs.
L-VDCC or RyR antagonism reduces hippocampal
neuroinflammatory markers during chronic
neuroinflammation
We evaluated the role of L-VDCC and RyR antagonism
on LPS-induced microglia activation in the hippocampus
by performing immunohistochemistry against MHC-II
(Figure 5A). Numerous activated microglia were present
throughout the hippocampi of LPS-infused rats, with few
present in aCSF-infused rats. MHC-II positive (MHC-II+)
cells were counted in specific hippocampal subfields
(Figure 5B, C, D). Very few activated microglia were
present in the CA1 subfield (Figure 5A), with no differ-
ences across any of the groups (P > 0.3). The CA3 and
DG (Figure 5C, D) subfields had more MHC-II+ cells,
and two-way ANOVAs revealed a significant main effect
of drug and group in the CA3 (F(2, 122) = 3.069, P = 0.050
and F(1, 122) = 33.642, P < 0.001, respectively) and a
Figure 4 Chronic LPS infusion increased hippocampal
synaptosomal uptake of 45Ca+2 and this increase was reduced
by treatment with nimodipine in vivo (A) or ex vivo (B and C).
(A) Baseline 45Ca+2 uptake by hippocampal synaptosomes isolated
from rats infused with LPS or aCSF for 4 weeks and treated with
vehicle or nimodipine. (B) 45Ca+2 uptake by hippocampal synaptosomes
isolated from rats infused with LPS or aCSF for 4 weeks and treated with
vehicle or nimodipine and additionally treated with ex vivo application
of 30 μM nimodipine. (C) Data from figures (A) and (B) for comparison
of baseline uptake and blocked uptake of 45Ca+2 with ex vivo
nimodipine. Data expressed as mean ± SEM. *Indicates a significant
difference from treatment-matched aCSF controls, †Indicates a
significant difference from LPS + vehicle rats, N.S. indicates no significant
differences. Significance determined by P< 0.05. LPS lipopolysaccharide,
aCSF artificial cerebrospinal fluid.
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91.203, P < 0.001). Post hoc analyses on the CA3 and
DG showed that LPS-infused rats treated with vehicle,
dantrolene, or nimodipine all had significantly more
MHC-II positive cells compared to their aCSF controls
(P < 0.02). In the CA3, dantrolene- and nimodipine-
treated LPS rats had significantly fewer MHC-II+ cells
compared to vehicle-treated LPS rats (P < 0.001 and
P = 0.011, respectively). In the DG, the LPS + dantrolene
rats had fewer MHC-II+ cells than the LPS + vehicle rats
(P = 0.028), but the LPS + nimodipine rats were not sig-
nificantly different (P > 0.1). Overall, the blockade of RyRs
and L-VDCCs reduces hippocampal microglia activation
induced by chronic LPS infusion. Furthermore, changes in
multiple biomarkers in response to drug treatment were
likely more robust in the dentate and CA3 regions of the
hippocampus, as compared to the CA1 region, due to the
fact that these regions typically demonstrate a more ro-
bust inflammatory response to chronic LPS infusion [6].
We then assessed astrocyte activation after chronic
LPS infusion by examining hippocampal GFAP gene ex-
pression (Figure 5E) and quantified GFAP immunohisto-
chemistry in hippocampal subfields (Figure 5F, G, H). A
two-way ANOVA revealed a trend toward interaction
between drug and group (P = 0.057) on hippocampal
GFAP gene expression, but there were no significant
differences between any of the groups. Similarly, immu-
nohistochemistry quantification revealed no significant
differences in the CA1 (Figure 5F), CA3 (Figure 5G), or
DG (Figure 5H), although there was a trend toward
significant interaction of drug and group on DG GFAP
expression (P = 0.082). Taken together with the MHC-II
immunohistochemistry data, these data demonstrate a
more significant role for microglia than astrocytes in LPS-
induced neuroinflammation.
We further elucidated the neuroinflammatory milieu of
the hippocampus following chronic LPS infusion by evalu-
ating several inflammatory genes in whole hippocampal
homogenate (Figure 6). Two-way ANOVA revealed that
Figure 5 Chronic LPS infusion increased activation of microglia but not astrocytes, and treatment with either dantrolene or
nimodipine reduced microglia activation. Activated microglia were quantified by counting MHC-II+ cells, and activated astrocytes were quantified
by densitometry of GFAP. Hippocampal immunohistochemistry against MHC-II/OX-6 (A) and GFAP was quantified (B, C, D, F, G, H) across specific
hippocampal subfields. Although the DG region in LPS-infused rats contains numerous immunoreactive objects, only those OX-6 immunoreactive
objects larger than 65 mm2 were included in analysis and are represented in the histograms. GFAP hippocampal gene expression (E) was also
quantified. (B) There was no change in the number of MHC-II+ cells in the CA1 subfield of the hippocampus. (C, D) There were significantly
more MHC-II positive cells in the CA3 (C) and DG (D) subfield of all LPS-treated groups compared to their aCSF controls. Dantrolene treatment
significantly reduced the number of MHC-II+ cells present in the CA3 and DG subfields, and nimodipine treatment significantly reduced the number of
MHC-II+ cells present in the CA3. (E) There was a trend toward a drug × group interaction for hippocampal GFAP gene expression, but no statistically
significant changes were observed. (F, G, H) There were no significant changes in the amount of GFAP in any of the hippocampal subfields due to
either LPS or drug treatment. Data expressed as mean ± SEM. *Indicates a significant difference from treatment-matched aCSF controls, †Indicates a
significant difference from LPS + vehicle rats. Significance determined by P < 0.05. LPS lipopolysaccharide, aCSF artificial cerebrospinal fluid, DG dentate
gyrus, GFAP glial fibrillary acid protein.
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gene expression was significantly affected by the LPS vs.
aCSF group (F(1, 40) > 4, P < 0.05), and TLR4, inducible
nitric oxide synthase (iNOS), and transforming growth
factor β (TGFβ) gene expression was significantly affected
by an interaction between drug and group (F(2, 40) > 3.5,
P < 0.05). Post hoc analyses revealed that the LPS + vehicle
rats had significant (P < 0.05) increases in gene expression
of IL-1β, TLR4, iNOS, TLR2, and TGFβ compared to the
aCSF + vehicle rats. Treatment with nimodipine decreased
the gene expression of IL-1β, TLR4, iNOS, and TGFβ
(P = 0.053 trend, P = 0.039, P = 0.085 trend, and P = 0.033,
respectively), while treatment with dantrolene decreased
gene expression of TLR4, iNOS, and TGFβ (P = 0.007,
P = 0.050, and P = 0.006, respectively). For IL-1β, iNOS,and TLR2 expression, dantrolene or nimodipine-treated
LPS rats that did not reach P < 0.05 were not significantly
different than their aCSF controls or LPS + vehicle rats,
indicating an intermediate reduction with drug treatment.
Discussion
Nimodipine and dantrolene differentially improved
memory deficits associated with LPS infusion
Nimodipine treatment resulted in a complete recovery
of spatial memory deficits induced by chronic LPS infu-
sion as measured by performance in the MWM. These
data implicate an important role of Ca+2 overloads in
neuroinflammation-induced memory deficits. The mech-
anism by which nimodipine improves spatial memory
may be by reduction of the slow after hyperpolarization
Figure 6 (See legend on next page.)
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Figure 6 Chronic LPS infusion increased gene and protein expression of several inflammatory markers and these increases were reduced
by treatment with either dantrolene or nimodipine. Gene expression of IL-1β (A), TLR4 (B), iNOS (C), TLR2 (D), and TGFβ (E) was significantly
increased in LPS + vehicle rats compared to aCSF + vehicle rats. In LPS rats, treatment with nimodipine significantly reduced expression of
TLR4 mRNA (B), TGFβ mRNA (E), IL-1α protein (G), and IL-1β protein (H) and led to a trend in reduction of the IL-1β gene ((A), P = 0.053) and
iNOS gene ((C), P = 0.085). In LPS rats, treatment with dantrolene significantly reduced the expression of TLR4 gene (B), iNOS gene (C), TGFβ
gene (E), IL-1α protein (G), and IL-1β protein (H). There was no significant change in TNFα gene expression (F). Data expressed as mean± SEM. *Indicates
a significant difference from treatment-matched aCSF controls, †Indicates a significant difference from LPS + vehicle rats, ¥Indicates significant difference from
aCSF + dantrolene rats. Significance determined by P<0.05. LPS lipopolysaccharide, aCSF artificial cerebrospinal fluid, TLR4 Toll-like receptor 4, TLR2 Toll-like
receptor 2, iNOS inducible nitric oxide synthase, TGFβ transforming growth factor β, TNFα tumor necrosis factor alpha.
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proved memory acquisition [37]. This would improve
neuronal sensitivity to relevant event-related stimuli,
which may be overshadowed by Ca+2 “noise” during
neuroinflammation. Indeed, blockade of tumor necrosis
factor alpha (TNFα) signaling during aging reduces age-
related increases in the sAHP and improves memory
[38], suggesting a relationship between neuroinflam-
mation, memory, and the enhancement of L-VDCCs.
Similarly, increased RyR dysregulation also underlies
age-associated Ca+2 dysregulation and increases in the
sAHP. In young rats, in vitro RyR blockade reduces the
sAHP to a lesser extent compared to L-VDCC antagonism
[39]. Aged neurons demonstrate prolonged increases in
intracellular Ca+2 levels that are RyR-dependent [40].
Oxidative stress present in aged rats increases the sAHP
by 50% and is dependent on RyRs, but not other sources
of Ca+2, including inositol triphosphate receptors and
L-VDCCs [36]. Additionally, L-VDCCs and RyRs inter-
act with each other: Ca+2 influx via L-VDCCs triggers
Ca+2-induced Ca+2 release via RyRs which in turn modu-
lates L-VDCC activity ([41];). Furthermore, a recent study
on patients with late onset AD demonstrated a genetic
interaction between L-VDCC and RyR mutations and
amyloid deposition [11], demonstrating the importance of
these two channels in the AD pathology.
In the present study, dantrolene treatment did not im-
prove memory to the same extent as nimodipine. However,
dantrolene was still able to normalize many biochemical
changes induced by chronic LPS infusion to the same ex-
tent as nimodipine. This discrepancy may be accounted for
by dantrolene’ s interaction with NMDAR function: RyR
activation is important for the amplification of NMDAR
signals [26,27]. While reduction of the sAHP by nimodi-
pine and dantrolene may increase relevant NMDAR
signaling, dantrolene may also reduce relevant NMDAR
signaling, leading to a disruption of memory performance.
On the surface, this concept may be in conflict with our
previous observation that NMDAR blockade with the
noncompetitive antagonist memantine improves memory
during chronic neuroinflammation [32], but memantine’ s
kinetics allow for relevant signals to pass through [42],
making its mechanism of neuroprotective and nootropic
effects more similar to nimodipine.Dantrolene and nimodipine normalize LPS-induced increases
in Arc and intracellular Ca+2
During chronic LPS infusion, Arc expression is increased
in the hippocampus, which parallels our previous studies
[32]. While Arc is required for late-LTP and memory
consolidation and Arc deficiency leads to memory
deficits [43], under normal circumstances, its expression
is sparse and specific [44], similar to electrophysiological
changes that take place during learning and memory.
Overexpression of Arc is most likely not beneficial to
memory during chronic neuroinflammation. Arc expres-
sion leads to endocytosis of AMPA receptors (AMPAR)
[45] and a decrease in AMPAR-mediated excitation
and induction of long-term depression (LTD; [46,47]).
Normally, the function of this may be to maintain
homeostatic synaptic scaling [48] and would be neuropro-
tective by decreasing glutamatergic postsynaptic activity.
However, an extended increase in Arc could cause a pro-
tracted decrease in synaptic excitability or LTD that could
eventually lead to increased synaptic elimination [49].
Treatment with dantrolene or nimodipine reduced LPS-
induced Arc increases. The mechanism by which dantro-
lene and nimodipine reduce Arc expression may be due to
a reduction in LPS-induced increases of intracellular Ca+2.
Indeed, Arc expression is known to be Ca+2-dependent
[29]. Several lines of evidence suggest that there is Ca+2
dysregulation during neuroinflammation. For one, neuro-
inflammation has been shown to reduce glutamate uptake
by [16,18] and potentiate glutamate release from [50,51]
glial cells. NMDAR blockade by memantine has been
shown to reduce Arc expression during chronic neuroin-
flammation [32], further supporting this concept. Potenti-
ated Ca+2 entry via L-VDCCs and RyRs by cytokines and
other pro-inflammatory markers have also been observed
([22,23,33]. By restoring normal intracellular Ca+2 levels,
dantrolene and nimodipine may prevent LPS-induced
overexpression of Arc. Indeed, LPS-infused rats had
significantly increased 45Ca+2 uptake. Previously, Ca+2
dysregulation induced by the pro-inflammatory cytokine
IL-1β has been observed directly using Ca+2 imaging
in vitro [52]. To the best of our knowledge, this is the first
study to directly document Ca+2 dysregulation following
in vivo chronic neuroinflammation as opposed to in vitro
acute neuroinflammation. Strikingly, nimodipine treatment
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induced increases in 45Ca+2 uptake. These data demon-
strate that the L-VDCC blockade is sufficient to reverse
LPS-induced Ca+2 dysregulation.
Potential mechanisms by which dantrolene and
nimodipine reduce neuroinflammation
Dantrolene and nimodipine dramatically reduce the number
of activated microglia in the hippocampus and reduce the
expression of various pro-inflammatory cytokines. It is not
clear from our data whether the anti-inflammatory effects of
dantrolene and nimodipine are due to direct action on the
microglia themselves or an indirect effect via normalization
of neuronal Ca+2 levels. Neurotoxicity of conditioned media
from activated microglia is reduced when drugs blocking
L-VDCCs or RyRs are applied to the microglia cultures
[12-14]. However, the in vivo anti-inflammatory effects
of these drugs are not so clear-cut. Following facial nerve
transection, nimodipine treatment improves motor neuron
survival without reducing microglia activation [53].
However, after ischemic-reperfusion injury, nimodipine
does improve behavioral outcomes while concurrently
reducing microglia activation [54]. Similarly, in vivo treat-
ment with dantrolene is neuroprotective and improves be-
havioral outcomes in various in vivo models of chronic
neurodegenerative disorders such as Huntington’s [55],
AD [56,57], and spinocerebellar ataxia [58]. Chronic
neuroinflammation is a pathological component in all
of these disorders [59-61]. However, these studies did
not examine microglia activation, making it difficult to
determine whether modulation of neuroinflammation
played a role in the improvement garnered by nimodi-
pine and dantrolene in these studies.
These drugs may act by directly reducing microglia acti-
vation. Intracellular Ca+2 is directly involved in microglia
activation. Ca+2 is required for LPS-mediated microglia
activation in vitro, with application of a Ca+2 chelator
sufficient to prevent activation and production of pro-
inflammatory species [62]. RyRs and L-VDCCs may be
involved in mediating Ca+2-associated microglia activation.
Microglia express mRNA of the RyR1 and RyR2 subtypes
and application of a RyR antagonist prevents LPS-induced
neurotoxicity mediated by microglia [14], suggesting a
direct role of RyRs in microglia activation. On the
other hand, L-VDCC expression on microglia is still
debated; the in vitro anti-inflammatory effect of nimodi-
pine may be mediated by off-target effects of nimodipine
[12]. Specifically, nimodipine may act by inhibiting the
microglia NOX pathway directly, resulting in reduced
superoxide production [13]. Earlier studies showed that
activation of L-VDCCs increased superoxide production
as well as Ca+2 influx in microglia, which could be
blocked by nifedipine, a drug closely related to nimodi-
pine [63]. Regardless of whether microglia expressfunctional L-VDCCs, it is possible that nimodipine is
exerting direct anti-inflammatory effects during chronic
LPS infusion.
L-VDCC blockers, such as dantrolene and nimodi-
pine, can also relax vascular smooth muscle by inhibit-
ing Ca+2 influx leading to vasodilation in the presence of
cerebral vasospasms induced by subarachnoid hemorrhage
that can lead to brain ischemia, oxidative stress, and neuro-
inflammation [64]. However, the vascular actions of these
drugs most likely do not underlie their beneficial effects in
the current study since LPS exposure upregulates the indu-
cible form of nitric oxide synthase leading to an elevated
release of nitric oxide [65] and subsequent vasodilation.
Microglia monitor the status of nearby neurons [66]
via a variety of channels and receptors. Importantly,
microglia can sense depolarization of nearby neurons via
K+ channels [67]. The data herein show that dantrolene
and nimodipine are both capable of reducing LPS-induced
increases in hippocampal Arc expression. Because Arc
expression requires intracellular Ca+2 [29], it makes
sense that these drugs are directly reducing intraneuronal
Ca+2 levels, ostensibly reducing neuronal depolarization,
which may in turn reduce activation of nearby microglia.
Furthermore, neurons suffering from Ca+2 overload are
known to alert microglia by release of chemokines [68].
Therefore, reduction of neuronal Ca+2 by nimodipine
and dantrolene may prevent activation of microglia by
neuronal-mediated mechanisms. Here, we did not observe
any effect of LPS or drug treatment on expression of CD200
receptor or ligand (data not shown), indicating that upregu-
lation of CD200 ligand on neurons is not mediating an anti-
inflammatory feedback mechanism similar to that which
is suggested above. Regardless of the specific mechan-
ism, these data suggest that treatment with dantrolene
or nimodipine is sufficient to break the self-propagating
cycle of neuroinflammation.
Conclusions
Neuroinflammation drives a self-propagating feed for-
ward cycle, where activated microglia release cytokines
and NO that are injurious to neurons, and injured neu-
rons release factors that also activate nearby microglia.
Cytokines also feed back onto microglial cytokine recep-
tors, triggering activation of additional nearby microglia.
Our model of chronic LPS infusion triggers this cascade:
after cessation of LPS infusion, neuroinflammation and
memory deficits persist after 5 weeks [29], suggesting that
even without LPS present, microglia that have already
been activated continue to maintain a pro-inflammatory
environment. The ability of dantrolene and nimodipine
to disrupt this cycle suggests that Ca+2 dysregulation is
a viable target for interrupting the cycle of neuroin-
flammation that may contribute to neurodegenerative
diseases such as AD.
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